Sodium Phosphate, Dibasic, Unspecified Form

Dosage for Sodium Phosphate, Dibasic is highly individualized and depends strictly on the indication and the patient's baseline electrolyte levels.

Bowel Preparation

For colonoscopy preparation using oral tablets, a typical regimen may involve 32 tablets (each containing a combination of monobasic and dibasic sodium phosphate) taken in divided doses. For example, 4 tablets every 15 minutes with 8 ounces of clear liquid for a total of 20 tablets on the evening before the procedure, followed by 12 tablets on the morning of the procedure. If using an oral solution, a common dose is 15-45 mL diluted in water, though many clinicians have moved away from high-dose oral phosphate solutions due to safety concerns.

Electrolyte Replenishment

For mild to moderate hypophosphatemia, oral doses of 250 mg to 500 mg of phosphorus (as phosphate salts) are typically given 3 to 4 times daily. For severe hypophosphatemia (serum phosphorus < 1.0 mg/dL), intravenous doses of 0.08 to 0.24 mmol/kg of body weight may be infused over 6 to 12 hours, with frequent monitoring of serum levels.

Sodium Phosphate, Dibasic must be used with extreme caution in children. For constipation in children aged 5 to 11, a rectal enema (half the adult dose) may be used under medical supervision. Oral phosphate for bowel prep is generally NOT recommended for children under the age of 18 due to the high risk of severe electrolyte shifts and dehydration. Always consult a pediatric specialist for precise weight-based dosing.

Renal Impairment

Sodium Phosphate, Dibasic is contraindicated (should not be used) in patients with significant renal impairment (creatinine clearance < 30 mL/min). In patients with mild to moderate impairment, doses must be significantly reduced, and phosphorus levels must be monitored every few hours during treatment.

Hepatic Impairment

No specific dose adjustments are usually required for liver disease, as the drug is cleared renally. However, patients with cirrhosis and ascites are at higher risk for fluid imbalances and should be monitored closely.

Elderly Patients

Patients over age 65 are at a significantly higher risk for acute phosphate nephropathy (kidney damage). Healthcare providers typically use the lowest effective dose and ensure the patient is aggressively hydrated before, during, and after administration.

• Hydration is Critical: You must drink large amounts of clear liquids (water, clear broth, apple juice) to prevent dehydration. Avoid red or purple liquids if preparing for a colonoscopy.
• Timing: For bowel prep, follow the exact schedule provided by your gastroenterologist. Taking the dose too late may result in an incomplete cleaning of the colon.
• Oral Tablets: Swallow tablets whole with a full glass of water. Do not crush or chew them, as this can alter the absorption rate.
• Storage: Store at room temperature (68°F to 77°F). Keep the container tightly closed and protect it from excessive moisture.

If you miss a dose during a bowel preparation regimen, contact your doctor's office immediately. Do not double the dose to catch up, as this can cause dangerous electrolyte spikes. Your procedure may need to be rescheduled if the prep is not completed correctly.

An overdose of Sodium Phosphate, Dibasic can be life-threatening. Symptoms include severe muscle cramping, tetany (uncontrolled muscle contractions), seizures, heart palpitations, and extreme thirst. In the event of a suspected overdose, call 911 or your local poison control center immediately. Treatment usually involves intravenous fluids and medications to lower phosphate and raise calcium levels.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or the timing of your dose without direct medical guidance.

Most patients taking Sodium Phosphate, Dibasic for bowel preparation will experience some level of gastrointestinal discomfort. These symptoms are generally expected due to the drug's mechanism of action:

• Nausea and Vomiting: Often occurring shortly after ingestion as the high salt concentration can irritate the stomach lining.
• Abdominal Bloating and Distension: A feeling of fullness or 'tightness' in the abdomen as water is drawn into the intestines.
• Abdominal Cramping: Mild to moderate pain as the intestines contract to move fluid through the system.
• Dizziness: Often a result of the rapid fluid shift and mild dehydration.

• Headache: Usually secondary to dehydration or changes in blood pressure.
• Chills: Some patients report feeling cold or shivery during the bowel cleansing process.
• Vomiting: While nausea is common, actual vomiting can lead to prep failure and electrolyte loss.

• Hypersensitivity Reactions: Rash, itching, or hives.
• Arrhythmias: Irregular heartbeats caused by rapid shifts in potassium or calcium levels.
• Syncope: Fainting due to a sudden drop in blood pressure (orthostatic hypotension).

> Warning: Stop taking Sodium Phosphate, Dibasic and call your doctor immediately or seek emergency care if you experience any of the following:

• Signs of Kidney Injury: Decreased urination, swelling in the ankles or feet, or unexplained fatigue. This may indicate acute phosphate nephropathy.
• Seizures: Even in patients without a history of epilepsy, severe electrolyte imbalances can trigger generalized tonic-clonic seizures.
• Severe Arrhythmia: Feeling like your heart is skipping beats, racing, or fluttering, which may be linked to QT prolongation.
• Tetany or Muscle Twitches: Signs of dangerously low calcium (hypocalcemia), which can lead to respiratory distress if the throat muscles are affected.
• Mental Status Changes: Confusion, disorientation, or extreme lethargy.

Sodium Phosphate, Dibasic is typically used for short-term indications. However, repeated use (such as chronic laxative abuse) can lead to:

• Chronic Kidney Disease (CKD): Permanent scarring of the kidney tubules (nephrocalcinosis).
• Secondary Hyperparathyroidism: The body overproduces parathyroid hormone in response to chronically high phosphate levels, leading to bone weakening.
• Electrolyte Dependency: The bowel may lose its natural ability to move waste without the stimulus of osmotic salts.

The FDA has issued a Black Box Warning for oral sodium phosphate products used for bowel cleansing. The warning highlights the risk of Acute Phosphate Nephropathy, a form of acute kidney injury caused by the deposition of calcium phosphate crystals in the renal tubules. This condition can lead to permanent loss of kidney function and the need for long-term dialysis. Risk factors include age over 55, dehydration, history of kidney disease, and the use of certain medications like ACE inhibitors or NSAIDs.

Report any unusual symptoms, especially changes in urinary output or heart rhythm, to your healthcare provider immediately.

Sodium Phosphate, Dibasic is a potent medication that requires careful medical oversight. It is not a 'simple' laxative; the rapid shifts in fluid and electrolytes it induces can be dangerous for patients with underlying health conditions. The most critical safety requirement is maintaining aggressive hydration. Patients must be able to consume and retain large volumes of clear liquids to mitigate the risk of kidney damage and severe dehydration.

WARNING: ACUTE PHOSPHATE NEPHROPATHY

• Rare but serious reports of acute phosphate nephropathy have been documented with the use of oral sodium phosphate products for bowel cleansing.
• Some cases resulted in permanent impairment of renal function and some patients required long-term dialysis.
• While some cases occurred in patients without identifiable risk factors, patients at increased risk include those who are: over age 55, hypovolemic (dehydrated), have increased bowel transit time (e.g., bowel obstruction), have active colitis, or have baseline kidney disease.
• Patients using medicines that affect renal perfusion or function (such as ACE inhibitors, ARBs, NSAIDs, and diuretics) are also at increased risk.

• Allergic Reactions: While rare, anaphylaxis can occur. Patients with a known allergy to sodium phosphate salts must avoid this medication.
• Renal Toxicity: The risk of nephrocalcinosis (calcium deposits in the kidney) is the primary concern. Baseline and post-procedure renal function tests are often required for high-risk patients.
• Cardiac Risks: Sodium Phosphate, Dibasic can cause significant changes in calcium and potassium levels, which may lead to QT prolongation and serious ventricular arrhythmias. It should be used with extreme caution in patients with a history of heart failure or recent myocardial infarction (heart attack).
• Seizure Risk: Electrolyte disturbances (low calcium, high sodium) can lower the seizure threshold. Patients with a history of seizures or those taking medications that lower the threshold should be monitored closely.

Healthcare providers typically order the following tests before and after administration of high-dose sodium phosphate:

• Basic Metabolic Panel (BMP): To check sodium, potassium, and chloride levels.
• Serum Creatinine and GFR: To assess kidney function.
• Serum Calcium and Phosphate: To monitor for hyperphosphatemia and hypocalcemia.
• Electrocardiogram (ECG): For patients with cardiac risk factors to monitor the QT interval.

Patients should avoid driving or operating heavy machinery for at least 24 hours after taking a bowel prep dose. The risk of sudden dizziness, fainting, or the urgent need for bowel movements makes these activities unsafe.

Alcohol should be strictly avoided while taking Sodium Phosphate, Dibasic. Alcohol is a diuretic that increases dehydration and can worsen electrolyte imbalances, significantly increasing the risk of kidney injury.

For bowel preparation, the medication is a one-time or two-time dose. If used as a supplement, do not stop taking it without consulting your doctor, as phosphate levels may crash, leading to muscle weakness and respiratory failure.

> Important: Discuss all your medical conditions, especially kidney, heart, or bowel problems, with your healthcare provider before starting Sodium Phosphate, Dibasic, Unspecified Form.

• Other Sodium Phosphate Products: Taking multiple phosphate-based laxatives (e.g., an oral solution plus an enema) dramatically increases the risk of toxic phosphate levels and acute kidney failure.
• Certain Bowel Preps: Do not combine with other osmotic laxatives unless specifically directed by a physician, as this can lead to severe dehydration.

• ACE Inhibitors and ARBs: Drugs like lisinopril or losartan affect how the kidneys handle blood pressure and filtration. Using these with Sodium Phosphate, Dibasic significantly increases the risk of acute phosphate nephropathy.
• Diuretics (Water Pills): Furosemide or hydrochlorothiazide can cause baseline dehydration and electrolyte depletion, making the osmotic effects of sodium phosphate more dangerous.
• NSAIDs: Common painkillers like ibuprofen or naproxen reduce blood flow to the kidneys, which can prevent the kidneys from clearing the excess phosphate load, leading to crystal deposition.

• Corticosteroids: These can cause the body to retain sodium, which may worsen the hypernatremia (high sodium) caused by the drug.
• Digoxin: Shifts in potassium and calcium levels caused by the phosphate salt can increase the risk of digoxin toxicity, leading to dangerous heart rhythms.
• Lithium: Sodium phosphate can affect lithium excretion, potentially leading to toxic lithium levels in the blood.

• Dairy Products: High-calcium foods like milk or cheese can bind to phosphate in the gut, reducing its effectiveness and potentially forming insoluble crystals.
• High-Sodium Foods: Can worsen the sodium load on the kidneys.
• Caffeine: Acts as a mild diuretic and may contribute to dehydration during bowel prep.

• Calcium Supplements: Should be avoided for 2 hours before and after taking phosphate to prevent binding.
• Vitamin D: High doses of Vitamin D increase the absorption of phosphate, which may lead to unexpectedly high serum levels.
• St. John's Wort: While no direct metabolic interaction exists, the potential for GI upset may be compounded.

• Serum Phosphate: Will obviously be elevated immediately after dosing.
• Serum Calcium: May appear falsely low due to binding with phosphate.
• Urinary Mineral Tests: Results for calcium and phosphate excretion will be skewed for 48-72 hours after use.

For each major interaction, the primary mechanism is usually either a pharmacodynamic effect (compounding the stress on the kidneys) or a physical interaction (binding in the gut). Management typically involves temporary discontinuation of blood pressure medications or NSAIDs 24-48 hours before the procedure, under a doctor's supervision.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers.

Sodium Phosphate, Dibasic must NEVER be used in the following circumstances:

• Severe Renal Impairment: Patients with a GFR < 30 mL/min cannot clear the phosphate load, leading to certain toxicity.
• Congestive Heart Failure (CHF): The high sodium content and fluid shifts can trigger acute pulmonary edema (fluid in the lungs).
• Bowel Obstruction or Perforation: Using an osmotic laxative against an obstruction can lead to bowel rupture.
• Gastric Retention or Ileus: If the stomach or intestines are not moving, the solution will sit and cause severe mucosal damage or vomiting.
• Toxic Megacolon: A complication of inflammatory bowel disease where the colon is dangerously dilated.
• Known Hypersensitivity: Any previous allergic reaction to sodium phosphate salts.

Conditions requiring a careful risk-benefit analysis include:

• Active Inflammatory Bowel Disease (IBD): Such as Crohn's or Ulcerative Colitis, as the salt can cause 'aphthoid-like' ulcers on the colon wall that mimic a flare-up.
• Unstable Angina: The stress of bowel prep can trigger cardiac events.
• Electrolyte Imbalances: Patients with pre-existing low calcium or high sodium.
• Impaired Gag Reflex: High risk of aspirating the salty solution into the lungs.

There is a high degree of cross-sensitivity between different phosphate salts (monobasic, dibasic, and potassium phosphate). If you have had a reaction to one, you are likely to react to the others.

> Important: Your healthcare provider will evaluate your complete medical history, including recent blood work, before prescribing Sodium Phosphate, Dibasic.

Sodium Phosphate, Dibasic is classified as FDA Pregnancy Category C. There are no adequate, well-controlled studies in pregnant women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The primary concern is the risk of maternal dehydration and electrolyte shifts, which can affect placental perfusion. Most gastroenterologists prefer PEG-based solutions for pregnant patients as they are not absorbed.

It is known that phosphate is excreted in human milk. However, when used as a one-time dose for bowel prep, the amount reaching the infant is likely minimal. Nevertheless, because of the potential for serious adverse reactions in nursing infants from electrolyte shifts, a decision should be made whether to discontinue nursing for 24 hours or to avoid the drug.

Safety and effectiveness in pediatric patients under age 18 have not been established for bowel cleansing. Reports of fatalities in children following the use of sodium phosphate enemas or oral solutions have occurred, usually due to severe hyperphosphatemia and hypocalcemia. Pediatric use is generally restricted to specialized hospital settings for electrolyte replacement.

Patients over 65 are at the highest risk for complications. Clinical trials have shown that elderly patients have a higher incidence of serious adverse events, including renal failure and arrhythmias. Physicians often recommend 'split-dose' regimens or alternative products for this population to ensure safety.

In patients with any degree of renal insufficiency, the kidneys cannot effectively excrete the phosphate load. This leads to a rapid rise in serum phosphorus, which then binds to calcium, depositing as crystals in the kidneys (nephrocalcinosis). This medication is strictly avoided in moderate-to-severe kidney disease.

While the liver does not process the drug, patients with advanced liver disease (Child-Pugh Class B or C) often have 'third-spacing' of fluids (ascites). The osmotic pull of sodium phosphate can dangerously deplete the intravascular volume in these patients.

> Important: Special populations require individualized medical assessment and often require alternative medications for bowel cleansing.

Sodium Phosphate, Dibasic acts as a saline osmotic laxative. In the intestinal lumen, the dibasic phosphate ions ($HPO_4^{2-}$) are only partially absorbed. This creates a high osmotic pressure that prevents the absorption of water and actually draws water from the interstitial space into the gut. This results in a significant increase in liquid stool volume, which mechanically stimulates the colon to evacuate. In the blood, it provides inorganic phosphorus, which is taken up by cells via sodium-phosphate cotransporters (NPT2a and NPT2c) to be used in phosphorylation reactions and ATP synthesis.

The onset of action for the laxative effect is typically 30 minutes to 3 hours after oral administration and 2 to 5 minutes after rectal administration. The duration of effect lasts until the bowel is cleared, usually 6 to 12 hours. The dose-response relationship is steep; small increases in dose can lead to much larger shifts in fluid and electrolytes.

| Parameter | Value |

|---|---|

| Bioavailability | 40% - 70% (as phosphate) |

| Protein Binding | Negligible |

| Half-life | 4 - 8 hours (in healthy renal function) |

| Tmax | 1 - 3 hours |

| Metabolism | None (Inorganic salt) |

| Excretion | Renal (>90%) |

• Molecular Formula: $Na_2HPO_4$ (Anhydrous)
• Molecular Weight: 141.96 g/mol (Anhydrous)
• Solubility: Highly soluble in water; insoluble in alcohol.
• Structure: Consists of two sodium cations ($Na^+$) and one hydrogen phosphate anion ($HPO_4^{2-}$). It often exists as a hydrate (heptahydrate is common).

It is categorized as a Saline Laxative and an Electrolyte Replenisher. It is related to other phosphate salts like Sodium Phosphate Monobasic and Potassium Phosphate.